Jill Gilbert, M.D.
- Professor of Medicine (Hematology/Oncology)
- Director, Hematology/Oncology Fellowship Program
Phone
Vanderbilt University Medical Center
777 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232-6307
777 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232-6307
Jill Gilbert, M.D.
- Professor of Medicine (Hematology/Oncology)
- Director, Hematology/Oncology Fellowship Program
615-343-4677
jill.gilbert@vumc.org
Vanderbilt University Medical Center
777 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232-6307
777 Preston Research Building
2220 Pierce Avenue
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Dr. Gilbert is a medical oncologist who specializes in head and neck cancer as well as thyroid cancer. She will primarily be involved in developing clinical trials of novel therapeutic agents for therapy of head and neck and thyroid cancers. Additionally, she is interested in the host immune response in the head and neck cancer survivor and in patients with advanced disease who receive molecularly targeted agents.
As Director of the Hematology/Oncology Fellowship Program, she is extensively involved in training physicians to become specialists in hematology and oncology. In this role, Dr. Gilbert develops and oversees a training program that includes all aspects of clinical hematology/oncology and laboratory-based research opportunities.
Education
- University of North Carolina, Chapel Hill, North Carolina, BS
Biology, May 1990 - University of Alabama at Birmingham School of Medicine, Magna Cum
Laude, MD, June 1994 - Internship, Internal Medicine, University of Alabama at
Birmingham, July 1995 - Residency, Internal Medicine, University of Alabama at
Birmingham, July 1997 - Chief Medical Resident, University of Alabama at Birmingham, May
1998 - Fellow, Medical Oncology and Hematology, Johns Hopkins School of
Medicine, July 2001
Research Emphasis
Research Description
Publications
- Ghiam MK, Mannion K, Dietrich MS, Stevens KL, Gilbert J, Murphy BA. Assessment of musculoskeletal impairment in head and neck cancer patients. Support Care Cancer [print-electronic]. 2017 Jul; 25(7): 2085-92. PMID: 28191589, PII: 10.1007/s00520-017-3603-1, DOI: 10.1007/s00520-017-3603-1, ISSN: 1433-7339.
- Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 Jun; 15(6): 761-70. PMID: 28596256, PII: 15/6/761, DOI: 10.6004/jnccn.2017.0101, ISSN: 1540-1413.
- Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J. Clin. Oncol [print-electronic]. 2017 May 5/10/2017; 35(14): 1542-9. PMID: 28328302, DOI: 10.1200/JCO.2016.70.1524, ISSN: 1527-7755.
- Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
- Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J. Clin. Oncol [print-electronic]. 2016 Dec 12/28/2016; JCO2016683300. PMID: 28029303, PMCID: PMC5455313, PII: 10.1200/JCO.2016.68.3300, DOI: 10.1200/JCO.2016.68.3300, ISSN: 1527-7755.
- Bond SM, Dietrich MS, Gilbert J, Ely EW, Jackson JC, Murphy BA. Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment. Support Care Cancer [print-electronic]. 2016 Oct; 24(10): 4433-42. PMID: 27225527, PII: 10.1007/s00520-016-3284-1, DOI: 10.1007/s00520-016-3284-1, ISSN: 1433-7339.
- Jackson LK, Ridner SH, Deng J, Bartow C, Mannion K, Niermann K, Gilbert J, Dietrich MS, Cmelak AJ, Murphy BA. Internal Lymphedema Correlates with Subjective and Objective Measures of Dysphagia in Head and Neck Cancer Patients. J Palliat Med [print-electronic]. 2016 Sep; 19(9): 949-56. PMID: 27227341, PMCID: PMC5011629, DOI: 10.1089/jpm.2016.0018, ISSN: 1557-7740.
- Weiss J, Grilley Olson J, Deal AM, Chera B, Weissler M, Murphy BA, Hayes DN, Gilbert J. Using the galactose-a-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. Cancer [print-electronic]. 2016 Jun 6/1/2016; 122(11): 1697-701. PMID: 26989991, DOI: 10.1002/cncr.29978, ISSN: 1097-0142.
- Jackson LK, Deng J, Ridner SH, Gilbert J, Dietrich MS, Murphy BA. Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer. Am J Hosp Palliat Care [print-electronic]. 2016 May; 33(4): 313-20. PMID: 25667146, PII: 1049909115569591, DOI: 10.1177/1049909115569591, ISSN: 1938-2715.
- Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol [print-electronic]. 2016 Feb; 53: 54-9. PMID: 26705063, PMCID: PMC4707116, PII: S1368-8375(15)00398-X, DOI: 10.1016/j.oraloncology.2015.11.020, ISSN: 1879-0593.
- Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann. Oncol [print-electronic]. 2016 Feb; 27(2): 318-23. PMID: 26598548, PMCID: PMC4722891, PII: mdv537, DOI: 10.1093/annonc/mdv537, ISSN: 1569-8041.
